The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.
Paris-based Rivercell raises $25M seed led by HV to build its AI Virtual Cell model that predicts how human cells respond to drugs. Explore how it works.
Tempus expands its collaboration with Moderna and Merck to support potential commercialization of a personalized cancer ...
Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million after GENGLYCOS approval. Explore ...
FDA approves Rhapsido (remibrutinib) for adults with symptomatic dermographism beyond CSU. Get the full details on this newly ...
A Dutch court barred Merck from making or selling Keytruda SC in eight European markets, ruling in Halozyme’s patent dispute. Read what the order means now.
Biohub, DOE, NIH, Google DeepMind, Meta and research partners pledge $1.8B for an open-source AI virtual cell. Read more: Explore the initiative's goals.
SurVaxM missed its overall survival endpoint in glioblastoma, but patients 65 and younger saw a significant benefit. Read the trial results and context.
Gate Bioscience expands its Lilly deal for hard-to-drug proteins, with potential value above $870m. Read the latest on the ...
AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share deal to gain RL-007 (inidascamine), a pro-cognitive candidate. Read full details.
RougeTx raised $58 million in Series A funding to advance its HHT treatment toward clinical development. See who backed the ...
Alector will receive $100M upfront as Genentech gains worldwide rights to its brain-penetrant GCase therapy for Parkinson’s.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results